Substance / Medication

Lurasidone

Overview

Active Ingredient
lurasidone
RxNorm CUI
1040028

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Lurasidone versus typical antipsychotics for schizophrenia.
Storman Dawid, Koperny Magdalena, Styczeñ Krzysztof et al. · Cochrane Database Syst Rev · 2025
PMID: 39831535Meta-AnalysisFull text (PMC)
Efficacy of lurasidone in adults with bipolar depression: A systematic review and meta-analysis of its impact on depressive symptoms and disability.
Aronica Rosario, Pagani Claudia, Favalli Virginia et al. · J Affect Disord · 2025
PMID: 40185408Meta-Analysis
Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose-response meta-analysis.
Lin Yu-Wei, Chen Yang-Chieh Brian, Hung Kuo-Chuan et al. · BMJ Ment Health · 2024
PMID: 39557452Meta-AnalysisFull text (PMC)
Systematic literature review and network meta-analysis of lurasidone, brexpiprazole and cariprazine for schizophrenia.
Phalguni Angaja, McCool Rachael, Wood Hannah et al. · Int Clin Psychopharmacol · 2023
PMID: 35916575Meta-Analysis
Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression.
Modugula Harika, Kumar Anoop · CNS Neurol Disord Drug Targets · 2020
PMID: 32124704Meta-Analysis
Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan.
Kishi Taro, Nosaka Tadashi, Sakuma Kenji et al. · Neuropsychopharmacol Rep · 2020
PMID: 32767739Meta-AnalysisFull text (PMC)
Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.
Arango Celso, Ng-Mak Daisy, Finn Elaine et al. · Eur Child Adolesc Psychiatry · 2020
PMID: 31758359Meta-AnalysisFull text (PMC)
Efficacy and safety of lurasidone versus placebo as adjunctive to mood stabilizers in bipolar I depression: A meta-analysis.
Wang Hui, Xiao Ling, Wang Hui-Ling et al. · J Affect Disord · 2020
PMID: 32056755Meta-Analysis
A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: confirmation with meta-analysis of other antipsychotic drugs.
Yoshikawa Akane, Li Jiang, Meltzer Herbert Y · Pharmacogenomics J · 2020
PMID: 31636356Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Lurasidone (substance)
SNOMED CT
703115008
UMLS CUI
C2003424
RxNorm CUI
1040028

Clinical Data

This intervention maps to 9 entities in the Healos knowledge graph.

4
Conditions
3
Biomarkers
1
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.